Evonik stock at EUR 20.97, down 0.24% before Xetra
Published on 11/04/2026 at 08:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSEvonik outlook strengthens after strong quarter
- Adjusted EBITDA rose 40 percent year on year to EUR 629 million in the third quarter.
- Evonik expects full-year 2026 adjusted EBITDA in the upper half of its EUR 2.0 billion to EUR 2.2 billion range.
- Sales increased 13 percent, while free cash flow reached EUR 369 million in the quarter.
Evonik stock traded at EUR 20.97 on Lang & Schwarz at 08:10 CET on Wednesday, November 4, 2026, 0.24 percent below the Xetra close of Tuesday, November 3, at EUR 21.02.
The real-time quote of Evonik stock reflected a cautious premarket tone after the specialty chemicals group reported stronger third-quarter earnings. According to the Evonik press release, adjusted EBITDA increased 40 percent year on year to EUR 629 million, while sales rose 13 percent to their strongest quarterly growth since the third quarter of 2022.
Profit outlook moves toward upper range
Evonik said its 2026 adjusted EBITDA result is now likely to reach the upper half of its EUR 2.0 billion to EUR 2.2 billion guidance range. The company also expects fourth-quarter earnings to exceed the prior-year figure. Free cash flow reached EUR 369 million in the third quarter, compared with EUR 300 million a year earlier.
The DAX market barometer provides the broader European equity setting for the session.
More news and analyses on Evonik stock cover the company's earnings, outlook and strategic developments.
